Abstract
Recent headline developments in immuno-oncology Immuno-oncology, a field of active clini cal development for over three decades [1], has assumed new prominence in oncology since 2013, with the approval of the checkpoint inhibitor agents Yervoy ® (Ipilumimab, BMS), Keytruda ® , (Pembrolimumab, Merck) and Opdivo ® (Nivolumab, BMS).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
